Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001037927 | SCV001201364 | uncertain significance | MHC class I deficiency | 2022-06-24 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 578 of the TAP2 protein (p.Ala578Val). This variant is present in population databases (rs78328107, gnomAD 0.2%). This variant has not been reported in the literature in individuals affected with TAP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 836733). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV001037927 | SCV001527399 | uncertain significance | MHC class I deficiency | 2018-04-17 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Neuberg Centre For Genomic Medicine, |
RCV005225212 | SCV005870917 | uncertain significance | MHC class I deficiency 1 | criteria provided, single submitter | clinical testing | The missense c.1733C>T(p.Ala578Val) variant in TAP2 gene has not been reported previously as a pathogenic variant nor a benign variant, to our knowledge. The p.Ala578Val variant has been reported with allele frequency of 0.03% in gnomAD Exomes. This variant has been reported to the ClinVar database as Uncertain Significance. The amino acid change p.Ala578Val in TAP2 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The amino acid Ala at position 578 is changed to a Val changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as a Variant of Uncertain Significance (VUS). | |
Ambry Genetics | RCV005286271 | SCV005952227 | uncertain significance | Inborn genetic diseases | 2025-01-23 | criteria provided, single submitter | clinical testing | The c.1733C>T (p.A578V) alteration is located in exon 10 (coding exon 9) of the TAP2 gene. This alteration results from a C to T substitution at nucleotide position 1733, causing the alanine (A) at amino acid position 578 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |